NanoViricides, Inc. NEW (NNVC): Price and Financial Metrics
GET POWR RATINGS... FREE!
NNVC Stock Price Chart Interactive Chart >
NNVC Price/Volume Stats
| Current price | $2.15 | 52-week high | $7.86 |
| Prev. close | $2.07 | 52-week low | $1.04 |
| Day low | $2.09 | Volume | 115,400 |
| Day high | $2.25 | Avg. volume | 66,193 |
| 50-day MA | $1.84 | Dividend yield | N/A |
| 200-day MA | $3.25 | Market Cap | 24.84M |
NanoViricides, Inc. NEW (NNVC) Company Bio
NanoViricides, Inc. is a biopharmaceutical company. The Company researches treatments for viruses such as AIDS/HIV, Hepatitis C, influenza, and Asian bird flu.
Latest NNVC News From Around the Web
Below are the latest news stories about Nanoviricides Inc that investors may wish to consider to help them evaluate NNVC as an investment opportunity.
NanoViricides (NYSEAMERICAN:NNVC) Issues Earnings ResultsNanoViricides (NYSEAMERICAN:NNVC) issued its earnings results on Monday. The company reported ($0.23) EPS for the quarter, missing the Zacks consensus estimate of ($0.20) by ($0.03), Fidelity Earnings reports. Shares of NNVC stock opened at $4.76 on Thursday. The stock has a market capitalization of $54.81 million, a price-to-earnings ratio of -5.88 and a beta of [] |
NanoViricides, Inc. (NYSEAMERICAN:NNVC) Short Interest UpdateNanoViricides, Inc. (NYSEAMERICAN:NNVC) was the target of a large drop in short interest in October. As of October 29th, there was short interest totalling 494,500 shares, a drop of 36.4% from the October 14th total of 777,000 shares. Currently, 4.5% of the companys stock are short sold. Based on an average trading volume of 2,500,000 [] |
NanoViricides, Inc.: NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical TrialsSHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel n |
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical TrialsSHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its first quarter of financial year 2022 with the Securities and Exchange Commission. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back, trader! |
NNVC Price Returns
| 1-mo | 34.38% |
| 3-mo | 7.50% |
| 6-mo | -54.35% |
| 1-year | -40.11% |
| 3-year | -57.00% |
| 5-year | -92.21% |
| YTD | -42.20% |
| 2021 | 29.62% |
| 2020 | 14.34% |
| 2019 | -37.25% |
| 2018 | -77.27% |
| 2017 | -17.76% |
Loading social stream, please wait...